此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI

2026年11月14日 更新者:Yomna Mahmoud Shokry Abdelrehim、Assiut University

Myocardial Tissue Characterization and Deformation Kinetics Following the Ross Procedure: A Prospective Multiparametric CMR Study

The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.

Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.

This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.

研究概览

地位

尚未招聘

条件

研究类型

观察性的

注册 (估计的)

44

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.

描述

Inclusion Criteria:

  1. Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
  2. Informed written consent to participate in serial prospective imaging.

Exclusion Criteria:

  1. Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
  2. Prior myocardial infarction or primary non-ischemic cardiomyopathy.
  3. Severe renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m²).
  4. Associated congenital heart disease causing volume overload ex: VSD and PDA.
  5. Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
  6. Standard contraindications to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Diffuse myocardial fibrosis
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure.

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
Diffuse myocardial fibrosis
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %)

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

次要结果测量

结果测量
措施说明
大体时间
Subclinical myocardial mechanical recovery
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS)

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
Subclinical myocardial mechanical recovery
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS)

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
Subclinical myocardial mechanical recovery
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Measured by 3D CMR feature-tracking strain analysis by global radial strain [GRS].

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
Subclinical myocardial mechanical recovery
大体时间:Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate.

Baseline up to two weeks before ROSS procedure and 1 year postoperatively.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年5月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年10月25日

首先提交符合 QC 标准的

2026年11月14日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月14日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CMR-ROSS

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅